Review
Oncology
Laura Evgin, Richard G. Vile
Summary: Chimeric Antigen Receptor (CAR) modified T cell therapy has significantly advanced the treatment of B cell malignancies, but faces challenges when applied to solid tumors. Combining oncolytic viruses (OVs) and adoptive T cell therapy (ACT) shows potential, but careful consideration is needed to maximize efficacy and minimize interference. While OVs and CAR T cells each offer unique benefits, not all virus-induced effects may be favorable for CAR T therapy.
Review
Immunology
Mahdie Jafari, Maryam Kadkhodazadeh, Mina Bahrololoumi Shapourabadi, Nasser Hashemi Goradel, Mohammad Ali Shokrgozar, Arash Arashkia, Shahriyar Abdoli, Zahra Sharifzadeh
Summary: Despite the approval of new drugs and targeted therapies, most cancer types remain difficult to treat due to tumor heterogeneity, immune system evasion, and the complex interaction between the tumor microenvironment and immune cells. Oncolytic virus (OV) immunotherapy, which uses viruses to selectively replicate within cancer cells and activate the immune system, has shown promising results. However, challenges such as off-target side effects and non-specific uptake limit its effectiveness as monotherapy. Combining OV with other biotherapeutic agents, such as antibodies and CAR-T cells, has been proposed to enhance the anti-tumor activities of OV.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Seyed-Mahmood Seyed-Khorrami, Arezou Azadi, Nasrin Rastegarvand, Ala Habibian, Hoorieh Soleimanjahi, Marek J. Los
Summary: Immunotherapy and virotherapy have emerged as new methods for cancer treatment, with better specificity and outcomes. Applying these strategies in the treatment of malignancies is of great significance, based on advances in understanding cancer cell biology and oncolytic viruses.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Yunmeng Wang, Ping Cheng
Summary: Oncolytic viruses (OVs) are emerging as therapeutically relevant anticancer agents, especially when combined with genetically modified bispecific T cell engagers (BiTEs). This combination strategy can overcome the limitations of BiTEs alone and provide targeted cytotoxicity to solid tumors.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2024)
Review
Pharmacology & Pharmacy
Alberto Reale, Arianna Calistri, Jennifer Altomonte
Summary: Oncolytic viruses are a new class of therapeutic agents with multiple mechanisms of action, including direct cancer cell-killing, immunotherapy, and gene therapy. Developing an effective delivery system, such as using carrier cells, is crucial to accelerate the clinical advancement of oncolytic viruses. Mesenchymal stem cells have been heavily investigated as carrier cells due to their inherent tumor tropism.
Review
Immunology
Ali Akbar Samadani, Arman Keymoradzdeh, Shima Shams, Armin Soleymanpour, Ali Rashidy-Pour, Houman Hashemian, Sogand Vahidi, Seyedeh Elham Norollahi
Summary: CAR T-cell therapy is a promising immunotherapy for cancer with the potential to treat a variety of solid tumors. By modifying T cells with CAR, it is possible to effectively eliminate certain cancers. Strategies for investigating risks and mitigating off-tumor consequences are crucial, and successful CAR T-cell therapy protocols can enhance the efficacy and safety of treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Oncology
Masmudur M. Rahman, Grant McFadden
Summary: Oncolytic viruses (OVs) are a novel cancer treatment modality that selectively target and kill cancer cells while sparing normal ones. Engineered OVs show great potential in clinical trials, but combination therapies with other treatments may further improve their efficacy.
Review
Oncology
Xin-Ying Tang, Yu-Shi Ding, Tao Zhou, Xu Wang, Yong Yang
Summary: CAR-T cell therapy has shown promising results in hematologic malignancies, but its efficacy in solid tumors is limited due to antigen heterogeneity, suboptimal trafficking, and immunosuppressive microenvironment. Combination with oncolytic viruses (OV) might be a novel solution to overcome these challenges and improve the therapeutic outcomes for non-hematologic malignancies.
Review
Hematology
Xuejin Gao, Jile Liu, Rui Sun, Jingkun Zhang, Xinping Cao, Yi Zhang, Mingfeng Zhao
Summary: The combination of CAR-T cell therapy and oncolytic virus therapy has been shown to be beneficial in the treatment of hematological malignancies, improving the treatment effect and complementing the disadvantages of individual therapies.
ANNALS OF HEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Vita Golubovskaya, Hua Zhou, Feng Li, Robert Berahovich, Jinying Sun, Michael Valentine, Shirley Xu, Hizkia Harto, John Sienkiewicz, Yanwei Huang, Lijun Wu
Summary: This study focused on developing novel CS1 CAR-T cells and bispecific CS1-BCMA CAR-T cells for targeting multiple myeloma. The experimental results demonstrated that these cells effectively killed multiple myeloma cells, showing promise for future clinical trials.
Review
Oncology
Bart Spiesschaert, Katharina Angerer, John Park, Guido Wollmann
Summary: Combinations of oncolytic viruses with specific small molecule compounds can help overcome limitations in their ability to replicate and kill tumors in clinical settings. This review focuses on mechanisms by which small molecules can synergize with oncolytic viruses to enhance viral replication, tumor cell killing, and antitumor immune responses.
Article
Multidisciplinary Sciences
Jiqin Zhang, Yongxian Hu, Jiaxuan Yang, Wei Li, Mingming Zhang, Qingcan Wang, Linjie Zhang, Guoqing Wei, Yue Tian, Kui Zhao, Ang Chen, Binghe Tan, Jiazhen Cui, Deqi Li, Yi Li, Yalei Qi, Dongrui Wang, Yuxuan Wu, Dali Li, Bing Du, Mingyao Liu, He Huang
Summary: A two-in-one approach to generate non-viral, gene-specific targeted CAR-T cells through CRISPR-Cas9 was successfully developed, demonstrating feasibility and efficacy in a preclinical study. An innovative type of anti-CD19 CAR-T cell with PD1 integration showed superior ability to eradicate tumor cells.
Review
Immunology
Xiaoling Qin, Fengjiao Wu, Chang Chen, Qi Li
Summary: Colorectal cancer is a common cancer with a serious impact on people's life and health. Although CAR-T cell therapy has shown good efficacy in hematological malignancies, it still faces many challenges in solid tumors such as colorectal cancer. New approaches are being proposed to address these challenges.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Yangyang Xie, Xiaotong Li, Jingyi Wu, Huiling Zeng, Hamza Boucetta, Binru Wang, Pei Yang, Wei He
Summary: This article summarizes the innovative strategy of adoptive immunotherapy through in vitro modifications to express synthetic chimeric antigen receptors (CAR) on T cells for cancer treatment. This approach allows T cells to recognize and bind tumor antigens via a single-chain variable fragment recognition domain, bypassing the restriction of major histocompatibility complex. The article reviews the structure/design of CAR-T cells, the evolution process of this technology, the theoretical foundation for CAR-T therapy, marketed products, and the latest preclinical and clinical research progress. Perspectives on the development and potential future applications of this technology, especially for hematological malignant and solid tumors, are also provided.
CHINESE CHEMICAL LETTERS
(2023)
Review
Oncology
Juan Miguel Cejalvo, Claudette Falato, Lorea Villanueva, Pablo Tolosa, Xavier Gonzalez, Mariona Pascal, Jordi Canes, Joaquin Gavila, Luis Manso, Tomas Pascual, Aleix Prat, Fernando Salvador
Summary: Immunotherapy has significantly advanced the field of oncology, but most breast cancer patients cannot benefit from it. The introduction of oncolytic viruses may be a promising treatment strategy, but further research is needed to understand their mechanisms of action, safety, and the implications of systemic therapy.
CANCER TREATMENT REVIEWS
(2022)
Review
Oncology
Ali Zarezadeh Mehrabadi, Fatemeh Roozbahani, Reza Ranjbar, Mahdieh Farzanehpour, Alireza Shahriary, Ruhollah Dorostkar, Hadi Esmaeili Gouvarchin Ghaleh
Summary: Cancer is a critical issue in the global health system, and novel therapeutic approaches such as CAR-T cell therapy and oncolytic viruses offer promising solutions to improve treatment efficacy with fewer complications. Combining CAR-T cell therapy with oncolytic viruses can enhance the effectiveness of treatment by targeting solid tumors and reducing the negative effects of the immune system, thus increasing the success rate in treating this hazardous disease.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Microbiology
Morteza Karami-Zarandi, Hadi E. G. Ghale, Reza Ranjbar
Summary: This study identified 16 hypervirulent K. pneumoniae isolates and found that curcumin exhibited optimal activity at 1/2 minimum inhibitory concentration. Curcumin showed appropriate antibiofilm, anti-efflux, and anticapsule activities. Considering the crucial role of biofilm, capsule, and efflux systems in the pathogenesis of hypervirulent K. pneumoniae, curcumin may be used to enhance treatment against Klebsiella.
FUTURE MICROBIOLOGY
(2022)
Review
Chemistry, Medicinal
Hamed Sadeghi-Dehsahraei, Hadi Esmaeili Gouvarchin Ghaleh, Reza Mirnejad, Karim Parastouei
Summary: This systematic review and meta-analysis evaluated the impact of bergamot and its nutraceutical compounds on lipid profiles. The results showed that bergamot supplementation significantly decreased total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels, while increasing high-density lipoprotein cholesterol levels. However, the studies on nutraceutical compounds containing bergamot showed inconsistent results, and further research is needed to establish their clinical efficacy in improving lipid profiles.
PHYTOTHERAPY RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Hamidreza Totonchi, Pooneh Mokarram, Saeed Karima, Ramazan Rezaei, Sanaz Dastghaib, Farhad Koohpeyma, Shokoofe Noori, Negar Azarpira
Summary: This study found that low-dose resveratrol (0.02 and 0.2 mg/kg) treatment after ischemia significantly reduced ALT and AST levels. Additionally, the expression of UPR pathway genes was significantly reduced in the resveratrol group compared to the control group. The histopathological changes induced by I/R were significantly improved in mice receiving lower doses of resveratrol.
BMC PHARMACOLOGY & TOXICOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Shahab Mahmoudvand, Hadi Esmaeili Gouvarchin Ghaleh, Farid Azizi Jalilian, Mahdieh Farzanehpour, Ruhollah Dorostkar
Summary: In this study, a multi-epitope vaccine against SARS-CoV-2 was designed based on structural proteins. B- and T-cell epitopes were identified and analyzed for antigenicity, toxicity, allergenicity, and similarity. Docking was performed for T-cell epitopes with corresponding HLA alleles and selected epitopes were included in the final construct. In silico evaluation showed potential immune response and further testing is required for safety and efficacy.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
(2023)
Article
Multidisciplinary Sciences
Kazem Hassanpour, Hadi Esmaeili Gouvarchin Ghaleh, Mostafa Khafaei, Abdolkarim Hosseini, Gholamreaza Farnoosh, Taleb Badri, Mostafa Akbariqomi
Summary: The potential advantages of sleep in suppressing cytokine storms and inflammation in COVID-19 based on immunopathogenesis are summarized. Sleep loss impairs immune function, while improving sleep quality and adjusting the circadian rhythm may help prevent infections and boost immunity. Sufficient (or even more) sleep duration may lower susceptibility to COVID-19 infection and increase antibody levels.
Article
Biochemistry & Molecular Biology
Majdedin Ghalavand, Maryam Moradi-Chaleshtori, Ruhollah Dorostkar, Samira Mohammadi-Yeganeh, Seyed Mahmoud Hashemi
Summary: This study investigated the role of the tumor microenvironment and purified exosomes in M2 to M1 macrophage polarization, highlighting its potential as cancer immunotherapy. The results demonstrated that treatment with rapamycin-exosomes induced polarization of M2 macrophages to M1, leading to improved macrophage functionality.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
(2023)
Review
Biochemistry & Molecular Biology
Mohammad Moradi, Hadi Esmaeili Gouvarchin Ghaleh, Masoumeh Bolandian, Ruhollah Dorostkar
Summary: Targeted treatment is crucial in cancer treatment, and the phage display technique offers an innovative approach for designing carriers with cancer diagnostic and therapeutic properties.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
(2023)
Article
Oncology
Akbar Ghorbani Alvanegh, Majid Mirzaei Nodooshan, Ruhollah Dorostkar, Reza Ranjbar, Bahman Jalali Kondori, Alireza Shahriary, Karim Parastouei, Soheil Vazifedust, Elmira Afrasiab, Hadi Esmaeili Gouvarchinghaleh
Summary: This study investigates the synergistic effects of mesenchymal stem cells (MSCs) infected with Newcastle Disease Virus (NDV) and Lactobacillus casei extract (L. casei) on the growth of colorectal cancer (CRC) cell line. The results demonstrate that MSCs carrying NDV and L. casei can promote apoptosis in CT26 cell line by increasing the production of LDH and ROS.
INFECTIOUS AGENTS AND CANCER
(2023)